Active	Status	Sponsor type	Region	Phase	Filter
2 Active 8 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
uprifosbuvir (IDX21437) / Merck (MSD)
2017-001463-21: MK-3682B in Hepatitis C Virus (HCV) Genotype 3 (GT3) participants	Ongoing	3	426	Europe	MK-3682B, MK-3682B, Tablet	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc	Treatment of hepatitis C virus (HCV) infection, Treatment of chronic hepatitis C virus (HCV) infection, Diseases [C] - Virus Diseases [C02]
2016-000620-26: MK-3682B Fixed Dose Combination (FDC) in Subjects with Chronic Hepatitis C Virus (HCV) Infection	Ongoing	2/3	160	Europe	MK-3682B, MK-3682B, Tablet	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.	Chronic Hepatitis C Infected Patient, Chronic Hepatitis C Infected Patient, Diseases [C] - Virus Diseases [C02]